ARCHIVES

Nixon Resignation Won’t Hurt Cancer Program, Might Lead To More Money; Weinberger Stays

This article is from The Cancer Letter archive.

Vol. 01 No. 28 | August 16, 1974

Download PDF Visit The Full Archive

Related Articles

If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.

March 16, 2007

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

October 25, 2013

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992

Biology Societies Recomend 15% Funding Increase for NIH

February 12, 1999

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001

International Cancer Genome Consortium Aims To Produce Data On 50 Cancer Types.

May 2, 2008